Verrica Pharmaceuticals Inc. Capital Expenditures
Verrica Pharmaceuticals Inc. (VRCA) reported Capital Expenditures of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $16.00K, a 75.38% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $27.00K, a 92.54% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $362.00K, a 19.87% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $302.00K, a 65.80% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $16.00K derived: sum of 2 quarters · filed 2026-03-11 | $27.00K derived: sum of 3 quarters · filed 2026-03-11 | $27.00K 10-K · filed 2026-03-11 | |
| 2024-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $27.00K derived: sum of 2 quarters · filed 2025-11-14 | $27.00K 10-Q · filed 2025-11-14 | $254.00K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $11.00K 10-Q · filed 2025-08-12 | $238.00K derived: sum of 3 quarters · filed 2025-08-12 | $303.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | $227.00K derived: sum of 2 quarters · filed 2025-03-11 | $292.00K derived: sum of 3 quarters · filed 2025-03-11 | $351.00K derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $292.00K derived: sum of 2 quarters · filed 2025-03-11 | $351.00K derived: sum of 3 quarters · filed 2025-03-11 | $362.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $124.00K derived: sum of 2 quarters · filed 2024-11-05 | $135.00K 10-Q · filed 2024-11-05 | $201.00K derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $70.00K 10-Q · filed 2024-08-14 | $136.00K derived: sum of 3 quarters · filed 2024-08-14 | $213.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $11.00K 10-Q · filed 2024-05-13 | $77.00K derived: sum of 2 quarters · filed 2024-05-13 | $154.00K derived: sum of 3 quarters · filed 2024-05-13 | $308.00K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $143.00K derived: sum of 2 quarters · filed 2024-02-29 | $297.00K derived: sum of 3 quarters · filed 2024-02-29 | $302.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $231.00K derived: sum of 2 quarters · filed 2023-11-09 | $236.00K 10-Q · filed 2023-11-09 | $473.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $159.00K 10-Q · filed 2023-08-08 | $396.00K derived: sum of 3 quarters · filed 2023-08-08 | $435.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $5.00K 10-Q · filed 2023-05-09 | $242.00K derived: sum of 2 quarters · filed 2023-05-09 | $281.00K derived: sum of 3 quarters · filed 2023-05-09 | $577.00K derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $276.00K derived: sum of 2 quarters · filed 2023-03-06 | $572.00K derived: sum of 3 quarters · filed 2023-03-06 | $883.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $335.00K derived: sum of 2 quarters · filed 2022-11-07 | $646.00K 10-Q · filed 2022-11-07 | $1.19M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $607.00K 10-Q · filed 2022-08-11 | $1.15M derived: sum of 3 quarters · filed 2022-08-11 | $1.26M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $311.00K 10-Q · filed 2022-05-09 | $855.00K derived: sum of 2 quarters · filed 2022-05-09 | $966.00K derived: sum of 3 quarters · filed 2022-05-09 | $1.08M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $655.00K derived: sum of 2 quarters · filed 2022-03-02 | $771.00K derived: sum of 3 quarters · filed 2022-03-02 | $1.47M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $227.00K derived: sum of 2 quarters · filed 2021-11-12 | $926.00K 10-Q · filed 2021-11-12 | $929.00K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $815.00K 10-Q · filed 2021-08-10 | $818.00K derived: sum of 3 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $699.00K 10-Q · filed 2021-05-07 | $702.00K derived: sum of 2 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $682.00K 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $679.00K 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $663.00K derived: sum of 2 quarters · filed 2020-03-13 | $757.00K derived: sum of 3 quarters · filed 2020-03-13 | $774.00K 10-K · filed 2020-03-13 | $275.00K 10-K · filed 2019-03-07 |
| 2018-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $107.00K derived: sum of 2 quarters · filed 2019-11-06 | $124.00K 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $111.00K 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $17.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |